Alexion Pharma (NASDAQ: ALXN) reported Q4 EPS of $1.13, $0.03 better than the analyst estimate of $1.10. Revenue for the quarter came in at $701 million versus the consensus estimate of $702.69 million.

GUIDANCE:

Alexion Pharma sees FY2016 EPS of $5.00-$5.20, versus the consensus of $5.50. Alexion Pharma sees FY2016 revenue of $3.05-3.10 billion, versus the consensus of $3.20 billion.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.